GB2279567A - Topical 8-hydroxyquinoline compositions - Google Patents
Topical 8-hydroxyquinoline compositions Download PDFInfo
- Publication number
- GB2279567A GB2279567A GB9412606A GB9412606A GB2279567A GB 2279567 A GB2279567 A GB 2279567A GB 9412606 A GB9412606 A GB 9412606A GB 9412606 A GB9412606 A GB 9412606A GB 2279567 A GB2279567 A GB 2279567A
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceutical composition
- composition according
- hydroxyquinoline
- psoriasis
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
Abstract
8-Hydroxyquinoline is useful in the topical treatment of inflammatory proliferative skin diseases, especially psoriasis, especially when applied from an essentially anhydrous vehicle.
Description
COMPOSITIONS FOR THE TREATMENT OF INFLANMATORY PROLIFERATIVE SKIN DISEASE AND THEIR USE
This invention relates to compositions for the topical treatment of inflammatory proliferative skin diseases, especially psoriasis, and their manufacture and use.
Psoriasis is associated with the rapid turnover of skin cells (hyperproliferation) accompanied by a loss of differentiation so that silvery white scales form on the surface of the skin. Additionally, the capillaries become tortuous and dilated and an inflammatory reaction occurs, so that the skin reddens. The elevated silvery white scales on a contrasting red background produce the unsightly lesions characteristic of psoriasis.
A number of methods are used for the topical treatment of psoriasis, but none is entirely satisfactory.
Historically, the earliest form of therapy involved the use of coal tar derivatives. These are sometimes effective but are extremely messy. Subsequently, the use of dithranol (1,8-dihydroxy-9-anthrone) was developed. This substance is very effective, but it causes irritation of the skin and staining both of the skin and adjacent materials, which are disadvantages especially in home treatment. Topical corticosteroids have also been used. Although these are clean and convenient to use, they are only suppressive in action and therefore only provide short term relief of symptoms. In addition, psoriasis treated with corticosteroids tends to relapse in a more resistant form, so that more aggressive therapy is later required.
The latest form of topical treatment of psoriasis is the use of synthetic Vitamin D derivatives. These derivatives are reasonably effective but have to be used in extremely low concentrations in order to avoid systemic calcitropic effects. Thus, it has been shown that increasing the concentration of the derivative in the composition above 0.005% w/w is liable to cause an increase in plasma calcium levels and, even at the 0.005% w/w level used in the marketed licensed product, there have been reports of increased plasma calcium levels. Such preparations moreover rarely clear the psoriasis, perhaps because of the very low strength used. Patients therefore have to continue treatment for extended periods which increases the risk of systemic side effects.Furthermore, a significant proportion of patients experience irritation and this restricts usage, particularly on delicate areas of the skin such as the face. Although it is not known for certain, the Vitamin D appears to alter calcium metabolism in the epidermal cells, which results in reduced cell proliferation and increased cell differentiation, leading to a correction of the abnormal pathophysiology of the epidermal cells and a return to normal skin growth and development.
We have now found that 8-hydroxyquinoline is effective in the treatment of psoriasis and other inflammatory proliferative skin diseases by topical application to the affected area of skin. More particularly, we have found that 8-hydroxyquinoline at a concentration of 0.25% in a simple ointment or gel has a rapid ameliorating effect on patients with psoriasis. It rapidly removes the scales on resistant patches of psoriasis, such as those which occur on the elbows and knees.
A possible explanation for the effectiveness of 8hydroxyquinoline may be that it deprives the epidermal cells of the calcium they need for rapid proliferation by chelating the calcium and thus rendering it unavailable.
However other calcium chelating agents are not effective against psoriasis. For example ethylene diamine tetracetic acid and its salts were tested in various formulations and found to have no clinical effect whatsoever. Similarly, other chelating agents, including penicillamine, glycine, dimercaprol, citric acid, and 5-chloro-7-iodo-8hydroxyquinoline (the topical antiseptic sold under the registered Trade Mark "Vioform") were all found to have no beneficial effect in the topical treatment of psoriasis.
8-Hydroxyquinoline is a white or slightly off-white solid which is relatively insoluble in water but dissolves in many organic solvents. When dissolved in anhydrous ethanol at a concentration of 1% w/w, it produces a clear almost colourless solution. On addition of water, e.g. 20% of the total volume, the 8-hydroxyquinoline remains in solution but the colour changes to yellow. This implies that 8-hydroxyquinoline exists in different forms, depending on whether or not water is present, viz a yellow form in the presence of water and a colourless form under essentially anhydrous conditions.
Trials have been carried out with both aqueous systems (e.g. aqueous gels) and essentially anhydrous systems (e.g. ointments or anhydrous gels) and it has been found that only the essentially anhydrous systems are effective in the treatment of psoriasis. Small quantities of water, e.g. 3 to 4% by weight, can be present in the essentially anhydrous compositions without them becoming inactive, but the desired therapeutic effect is lost if more than a small amount of water is present. This loss of activity is associated with the development of the yellow colour shown by 8-hydroxyquinoline in the presence of water and the presence or absence of this yellow colour thus provides a convenient way of determining whether a composition contains too much water to be active.It is thus a very simple matter to determine by experiment how much water a particular formulation can tolerate before it becomes inactive.
Water is not the only substance capable of rendering 8-hydroxyquinoline unavailable and, in consequence, without useful therapeutic effect. More particularly, acids and bases render 8-hydroxyquinoline unavailable by either converting it into a salt or limiting its release by hydrogen bond formation. Also substances such as polyhydric alcohols, polyethylene glycol, polyethylene glycol ethers and esters and non-ionic surfactants in general prevent release of 8-hydroxyquinoline into the skin from the phase containing it. The presence of such substances in the compositions of the invention must therefore be avoided.It is believed that all such substances which render 8-hydroxyquinoline therapeutically unavailable have the property already noted of converting it into a yellow form, a colour change which is believed to be associated with disturbance of the intramolecular hydrogen bonding of the 8-hydroxyquinoline, believed to be a prerequisite for efficient dermatological availability.
The compositions of the invention are thus white (colourless) rather than yellow (unless a yellow colouring agent is added).
The present invention accordingly provides a pharmaceutical composition for topical application comprising 8-hydroxyquinoline in free form dissolved in a pharmaceutically acceptable essentially anhydrous solvent.
Such compositions preferably comprise from 0.01 to 5.0% by weight, more preferably from 0.1 to 1.0% by weight, most preferably 0.1 to 0.5% by weight, of 8-hydroxyquinoline.
The essentially anhydrous solvent is preferably paraffin or another topically acceptable, oleophilic, and waterimmiscible solvent. A mixture of white soft paraffin and isopropyl myristate has the required properties and is preferred.
The pharmaceutical composition may further comprise a lipid soluble antioxidant which is chemically inert towards 8-hydroxyquinoline to protect the 8-hydroxyquinoline from atmospheric oxidation.
The pharmaceutical compositions may also comprise a topical corticosteroid, for example, betamethasone valerate, hydrocortisone, or another corticosteroid known to be suitable for topical application, in an amount of 0.01 to 1.0% by weight. These compositions are useful for treating cases where there is excessive inflammation present.
These pharmaceutical compositions are preferably for use in the treatment of an inflammatory proliferative skin disease, especially psoriasis.
The present invention further provides 8hydroxyquinoline in free form for use in the treatment of, and in the manufacture of a medicament for the treatment of, an inflammatory proliferative skin disease, especially psoriasis, and a method of treating an inflammatory skin disease, especially psoriasis, which comprises applying 8hydroxyquinoline in free form to skin affected by such disease.
Although the present invention is primarily concerned with the treatment of psoriasis, it is within the scope of the invention to use 8-hydroxyquinoline in the treatment of other inflammatory skin conditions in which hyperproliferation or thickening occurs, e.g. chronic eczema/dermatitis.
While a simple ointment containing 8-hydroxyquinoline in white soft paraffin is (as noted above) effective in the present invention, it is desirable to reduce the greasiness of the formulation while retaining the 8-hydroxyquinoline in an essentially anhydrous oleophilic environment. To achieve this objective, the compositions of the invention may be provided in the form of an oil-in-water semi-solid emulsion, in which the 8-hydroxyquinoline is dissolved in the discontinuous oil phase. The aqueous phase of such compositions must have a substantially neutral pH to ensure that the partition of 8-hydroxyquinoline is strongly in favour of the oil phase. In these circumstances, even though the continuous phase is aqueous, the 8hydroxyquinoline is present in an essentially anhydrous environment because of the very low solubility of water in the dispersed oily phase.Such a composition may contain over 50% of a dispersed oil phase in which the 8hydroxyquinoline is dissolved. Although the lipid phase is preferably preponderantly white soft paraffin, chosen for its inertness and water immiscibility, a small amount of isopropyl myristate is preferably added to improve emolliency. In addition, since 8-hydroxyquinoline may be subject to atmospheric oxidation, a small concentration of an antioxidant, may be included. It is also preferable that the aqueous phase contains a preservative, preferably phenoxyethanol in an amount of 0 to 0.2 by weight. This is because the 8-hydroxyquinoline, which is itself an antiseptic, is held almost entirely in the lipid phase.
In an alternative embodiment of the invention, the 8hydroxyquinoline is provided as a therapeutically active gel by dissolving in it in free form in an essentially anhydrous pharmaceutically acceptable solvent and gelling with a thickener. For example, ethanol may be used which forms a clear colourless gel on the addition of hydroxypropyl cellulose. A small proportion of a soluble inert lipid, such as isopropyl myristate may be added to reduce the drying effect of the alcohol. Again, a small concentration of an antioxidant may be added. The amount of thickener to be added is adjusted to produce a final formulation varying from a slightly viscous liquid, for application as a lotion, to a semi-solid gel.
The following examples illustrate the invention.
Parts are by weight.
EXAMPLE 1
Most Preferred Range Range 8 -hydroxyquinoline 0.1, 0.25, 0.5 or 0.01 - 5.0 1.0 White Soft Paraffin 40.0 10 - 50 BP Isopropyl Myristate 10.0 0 - 30 BP Cetostearyl Alcohol 7.0 5 - 10 BP Sodium Lauryl 1.0 0.5 - 2.0 Sulphate BP Phenoxyethanol BP 0.1 0 - 0.2 Purified Water BP to 100.0 The formulation is made as follows: 1. Melt together the White Soft Paraffin (40 parts),
isopropyl myristate (10 parts) and Cetostearyl
Alcohol (7 parts) by heating to 700C.
2. Dissolve 8-hydroxyquinoline (0.5 parts) in the heated
oily phase so obtained.
3. Boil water (41.35 parts) thoroughly to remove any
dissolved oxygen and allow to cool to 700C.
4. Dissolve Sodium Lauryl Sulphate (1 part) and
Phenoxyethanol (0.1 part) in the water at 700C.
5. Add the aqueous phase so obtained to the oily phase
and homogenise continuously, avoiding aeration,
allowing the mixture to cool until semi-solid, to
produce an almost white cream.
6. Pack into aluminium collapsible tubes.
EXAMPLE 2
Most Preferred Range Range 8-hydroxyquinoline 0.1, 0.25, 0.5 or 0.01 - 2.0 1.0 Isopropyl myristate 10.0 5 - 15 BP Hydroxypropyl 3.0 0.5 - 3.5 Cellulose* BP Ethanol BP to 100.0 * - Klucel HF, Aqualon
The formulation is made as follows: 1. Dissolve the 8-hydroxyquinoline in the alcohol.
2. Add the isopropyl myristate and mix well.
3. Warm to 50-600C.
4. Add the hydroxypropyl cellulose slowly with
continuous mixing, avoiding aeration.
5. Allow to cool with occasional mixing to form a clear
colourless gel.
6. Pack into a bottle or aluminium tube depending on the
viscosity.
The preparation should be applied twice daily to the affected areas of psoriasis. For thin areas of psoriasis a concentration of 0.1 to 0.5 8-hydroxyquinoline may be sufficient, while for the thicker areas a concentration of 0.5t or 1.0% 8-hydroxyquinoline may be required. The preparation is non-irritant, it produces no staining, and has no effect on systemic calcium levels. It has been shown to be at least as effective as Vitamin D derivatives in some subjects, and even more effective in others. 8hydroxyquinoline is particularly useful in the treatment of resistant areas of psoriasis which may have to be treated for extended periods.
If desired, betamethasone valerate may be incorporated in the above formulations in a concentration of 0.1t by weight.
Claims (19)
1. A pharmaceutical composition for topical application comprising 8-hydroxyquinoline in free form dissolved in a pharmaceutically acceptable essentially anhydrous solvent.
2. A pharmaceutical composition according to claim 1 wherein 8-hydroxyquinoline is present in amount of from 0.01 to 5.0% by weight.
3. A pharmaceutical composition according to claim 2 wherein 8-hydroxyquinoline is present in an amount of from 0.1 to 1.0 by weight.
4. A pharmaceutical composition according to claim 1, 2, or 3 wherein the said solvent is oleophilic and water-immiscible.
5. A pharmaceutical composition according to claim 4 wherein the essentially anhydrous oleophilic, waterimmiscible solvent comprises a mixture of white soft paraffin and isopropyl myristate.
6. A pharmaceutical composition according to any one of claims 1 to 5 which also comprises an antioxidant.
7. A pharmaceutical composition according to any one of the preceding claims which also comprises a topical corticosteroid.
8. A pharmaceutical composition according to claim 7 wherein the topical corticosteroid is betamethasone valerate in an amount of from 0.01 to 1.0% by weight.
9. A pharmaceutical composition according to any one of claims 1 to 8 wherein the essentially anhydrous solution of 8-hydroxyquinoline is dispersed in an aqueous phase which has a substantially neutral pH.
10. A pharmaceutical composition according to claim 9 wherein the said aqueous phase contains an anionic dispersing agent.
11. A pharmaceutical composition according to claim 9 or 10 wherein 0 to 0.2 by weight of phenoxyethanol is dissolved in the aqueous phase.
12. A pharmaceutical composition according to claim 1, 2 or 3 in the form of a gel in which the 8hydroxyquinoline in free form is dissolved in an essentially anhydrous pharmaceutically acceptable solvent gelled with a thickener.
13. A pharmaceutical composition according to claim 12 wherein the said solvent is ethanol and the said thickener is hydroxypropylcellulose.
14. A pharmaceutical composition according to any one of claims 1 to 13 for use in the treatment of an inflammatory proliferative skin disease.
15. A pharmaceutical composition according to claim 14 wherein the inflammatory proliferative skin disease is psoriasis.
16. Use of 8-hydroxyquinoline in free form in the manufacture of a medicament for the treatment of an inflammatory proliferative skin disease.
17. Use according to claim 16 wherein the medicament is as defined in any of claims 1 to 13.
18. Use according to claims 16 or 17 wherein the inflammatory proliferative skin disease is psoriasis.
19. A pharmaceutical composition according to claim 1 substantially as hereinbefore described.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9412606A GB2279567B (en) | 1993-07-05 | 1994-06-23 | Compositions for the treatment of inflammatory proliferative skin disease and their use |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939313863A GB9313863D0 (en) | 1993-07-05 | 1993-07-05 | Glazing security system |
| GB9412606A GB2279567B (en) | 1993-07-05 | 1994-06-23 | Compositions for the treatment of inflammatory proliferative skin disease and their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB9412606D0 GB9412606D0 (en) | 1994-08-10 |
| GB2279567A true GB2279567A (en) | 1995-01-11 |
| GB2279567B GB2279567B (en) | 1997-04-02 |
Family
ID=26303182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB9412606A Expired - Fee Related GB2279567B (en) | 1993-07-05 | 1994-06-23 | Compositions for the treatment of inflammatory proliferative skin disease and their use |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2279567B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5972920A (en) * | 1998-02-12 | 1999-10-26 | Dermalogix Partners, Inc. | Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders |
| WO2003032944A1 (en) * | 2001-10-12 | 2003-04-24 | Aq+ Plc | Anti-microbial composition comprising a metal ion chelating agent |
| FR2943914A1 (en) * | 2009-04-06 | 2010-10-08 | Fabre Pierre Dermo Cosmetique | MOISTURE BOTTLE COMPRISING A PHARMACEUTICAL COMPOSITION |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB643860A (en) * | 1946-04-15 | 1950-09-27 | Ethan Allan Brown | Improvements in or relating to liquid antiseptics |
| GB981144A (en) * | 1963-03-25 | 1965-01-20 | Licencia Talalmanyokat | A pharmaceutical formulation for the treatment of dermatophytoses |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4038388A (en) * | 1974-03-29 | 1977-07-26 | Paterson Zochonis & Company Limited | Antimicrobial compositions |
| IE60024B1 (en) * | 1987-02-03 | 1994-05-18 | Stiefel Laboratories Ltd | Microemulsions |
-
1994
- 1994-06-23 GB GB9412606A patent/GB2279567B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB643860A (en) * | 1946-04-15 | 1950-09-27 | Ethan Allan Brown | Improvements in or relating to liquid antiseptics |
| GB981144A (en) * | 1963-03-25 | 1965-01-20 | Licencia Talalmanyokat | A pharmaceutical formulation for the treatment of dermatophytoses |
Non-Patent Citations (4)
| Title |
|---|
| Chemical Abstracts 84:169598 & Pharmazic 31(2), pages 121-4 (1976) * |
| Chemical Abstracts 88:55014 & Pharmazic 32(8-9), pages 507-8(1977) * |
| Chemical Abstracts 97:133427 & Pharmazic 37(3), pages 192-4 (1982) * |
| J.Pharm.Sci. 71(5), pages 585-7 (1982) * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5972920A (en) * | 1998-02-12 | 1999-10-26 | Dermalogix Partners, Inc. | Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders |
| WO2003032944A1 (en) * | 2001-10-12 | 2003-04-24 | Aq+ Plc | Anti-microbial composition comprising a metal ion chelating agent |
| CN100384422C (en) * | 2001-10-12 | 2008-04-30 | 爱克加股票上市公司 | Anti-microbial composition comprising a metal ion chelating agent |
| FR2943914A1 (en) * | 2009-04-06 | 2010-10-08 | Fabre Pierre Dermo Cosmetique | MOISTURE BOTTLE COMPRISING A PHARMACEUTICAL COMPOSITION |
| WO2010116078A1 (en) * | 2009-04-06 | 2010-10-14 | Pierre Fabre Dermo-Cosmetique | Foaming pharmaceutical composition that does not contain a propellant gas |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2279567B (en) | 1997-04-02 |
| GB9412606D0 (en) | 1994-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5422361A (en) | Stable cream and lotion bases for lipophilic drug compositions | |
| US5110809A (en) | Antifungal gel formulations | |
| US5990100A (en) | Composition and method for treatment of psoriasis | |
| US5002938A (en) | Antifungal gel formulations | |
| US5061700A (en) | Glyceryl acetate ointment vehicles | |
| CA2301009C (en) | Skin care compositions and use | |
| JPH032118A (en) | Humectant excipient for topical application of vitamin a acid | |
| FI88582B (en) | FRAMEWORK FOR THE FRAMEWORK OF METRONIDAZOLE MANUFACTURERS | |
| KR20110096054A (en) | Perfluorocarbon gel formulations | |
| JPH0148885B2 (en) | ||
| US5817675A (en) | Compositions for the treatment of psoriasis and their use | |
| JP2015530380A (en) | Composition for treating psoriasis | |
| JPH0463852B2 (en) | ||
| JPS58225009A (en) | Pharmaceutical preparation of corticosteroid for external use | |
| JP7268132B2 (en) | topical composition | |
| FR2491333A1 (en) | TOPICALLY ADMINISTRATIVE PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-INFLAMMATORY STEROIDS | |
| GB2279567A (en) | Topical 8-hydroxyquinoline compositions | |
| AU2004262934B2 (en) | Topical composition comprising terbinafine and hydrocortisone | |
| JP5125122B2 (en) | Adapalene-containing external preparation composition | |
| JP4835411B2 (en) | Adapalene-containing external preparation composition | |
| FR2588474A1 (en) | SYNERGETIC ANTI-INFLAMMATORY COMPOSITIONS BASED ON A CORTICOSTEROID AND AN AGONIST BETA | |
| FI118953B (en) | Inflammatory, nimesulide containing substance for external use | |
| JP5233149B2 (en) | Adapalene-containing external preparation composition | |
| JPH0366618A (en) | Pharmaceutical compound | |
| NZ235054A (en) | Gel formulation comprising imidazole antifungal agent and a 17-ester steroid anti-inflammatory agent with a co-solvent system and a gelling agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 20000623 |